Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Evolus Inc EOLS.OQ EOLS.O is expected to show a rise in quarterly revenue when it reports results on August 5 for the period ending June 30 2026
The Newport Beach California-based company is expected to report a 17.6% increase in revenue to $81.603 million from $69.39 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data. (Majority is on Total Revenue Basis)
LSEG's mean analyst estimate for Evolus Inc is for a loss of 3 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Evolus Inc is $14.00, about 139.7% above its last closing price of $5.84
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.12 | -0.13 | -0.05 | Beat | 61.5 |
Dec. 31 2026 | 0.06 | 0.05 | 0.05 | Met | 0 |
Sep. 30 2025 | -0.17 | -0.17 | -0.11 | Beat | 36.2 |
Jun. 30 2025 | -0.10 | -0.11 | -0.23 | Missed | -113 |
Mar. 31 2025 | -0.17 | -0.15 | -0.15 | Met | -3 |
Dec. 31 2024 | 0.04 | 0.04 | 0.04 | Met | 5.3 |
Sep. 30 2024 | -0.09 | -0.10 | -0.16 | Missed | -64.1 |
Jun. 30 2024 | -0.05 | -0.05 | -0.04 | Beat | 23.1 |
This summary was machine generated August 3 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Evolus
See all newsEvolus Inc reports results for the quarter ended June 30 - Earnings Summary
Evolus Q2 revenue rises 21%, lifts 2026 outlook
Brief: Evolus Q2 Product Revenue USD 83.35 Million
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe